Business Context and Reporting Period
This Form 6-K filing by Enlivex Ltd. (formerly Enlivex Therapeutics Ltd.) covers the month of February 2026. The primary purpose of this report is to disclose a corporate name change approved by shareholders and finalized with the Israeli Registrar of Companies.
Key Corporate Action
- Shareholder Approval: On February 3, 2026, shareholders voted to change the company name from "Enlivex Therapeutics Ltd." to "Enlivex Ltd."
- Official Registration: On February 10, 2026, the Registrar of Companies in Israel issued a Certificate of Change of Name effecting the new name.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event and does not contain financial statements or performance data.
Material Changes
The only material change disclosed is the legal name of the registrant. There are no reported changes to financial performance, operational scope, or capital structure within this document.
Outlook and Risks
The filing contains no management commentary, financial guidance, risk factors, or discussion of contingencies. The document strictly addresses the administrative completion of the name change.
Investor Verification Checklist
- Verify the new legal name "Enlivex Ltd." in subsequent filings and stock exchange listings.
- Confirm that the name change does not alter the company's existing registration statements (Forms S-8, F-3, F-3MEF) referenced in the filing.
- Review the attached Exhibit 99.1 (Certificate of Change of Name) for any specific conditions attached to the name change.